Pipeline

OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED).

A Focus on Ocular Therapies

Asset	Indication	Pre-Clinical
OK-101	Dry Eye	started phase 2 in Q2/2023
	Uveitis
	Allergic Conjunctivitis
	Ocular Pain
OK-201	Discovery Program

Drug	Indication	Stage
OK-101	Dry Eye	Phase 1^*
	Uveitis	Pre-Clinical
	Allergic Conjunctivitis	Pre-Clinical
	Ocular Pain	Pre-Clinical
OK-201	Discovery Program

^*started phase 2 in Q2/2023

OK-101 Development Timeline